In the first instance, I am aware of the side effect profile noted with finasteride.  I've also read the clinical studies describing its utility in the setting of pattern hair loss.  As you may be aware finasteride is a specific inhibitor of the type two 5 alpha-reductase enzyme, the enzyme implicated in the conversion of testosterone to the pathologic metabolite 5 alpha-dihydrotestosterone.  However, because both 5 alpha-reductase (5AR) isoforms (type 1 and type 2) may play a role in patten hair loss, the activity of type 1 5AR is still operative even in the face of therapeutic challenge with finasteride.

What makes HairGenesis® different from all the rest?  Let's start with the basics.  First, we're in the business of selling a patent pending, USPTO trademark registered, line of hair loss treatment products.  We are the only non-drug hair loss treatment line supported with published peer-reviewed IRB monitored clinical research.  Our latest university-based research study demonstrates a novel mechanism of action and our patent pending application articulates the novelty of our most recently developed dual-mechanism formula. 

For people concerned about hair loss, many myths and half-truths abound, but useful information can be difficult to put your hands on. Therefore, an objective overview of pattern hair loss is desirable.  

In healthy well-nourished males and females the most common form of hair loss is androgenetic alopecia (AGA), also known as pattern hair loss. The disorder affects approximately 40 million American men.  It may be a shock to learn that common pattern hair loss affects 20 million American women. The difference between the genders is that a woman suffering hair loss usually retains her juvenile hairline but experiences loss of density behind the leading edge. In men, a distinct pattern manifests where the frontal hair line recedes at the same time that a thinning zone expands from the posterior crown. In more pronounced cases, these zones meet and the person is said to be clinically bald.